DYRK2

Across TCGA pan-cancer cohorts, DYRK2 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of DYRK2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where DYRK2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types DYRK2 is over-expressed in tumor, although a few such as COAD and READ show the opposite, repressed pattern.

KIRP, BLCA, and KIRC are the cancer types where DYRK2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DYRK2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	Female	All	+1.433	<.001	11	view →
BLCA	All	III,IV	+0.987	<.001	11	view →
KIRC	Female	All	+0.962	<.001	11	view →
COAD	Female	All	−1.071	<.001	10	view →
LIHC	All	II,III,IV	+0.945	<.001	9	view →
HNSC	All	All	+0.698	<.001	9	view →
LUAD	Male	All	+1.060	<.001	8	view →
STAD	Male	II,III,IV	+1.029	<.001	8	view →
LUSC	Male	II,III,IV	+0.914	<.001	7	view →
BRCA	All	II,III,IV	+0.557	<.001	6	view →
CHOL	Male	All	+2.736	<.001	5	view →
ESCA	All	All	+1.233	.004	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

DYRK2–KIRP

Open the KIRP breakdown →